230 related articles for article (PubMed ID: 21348320)
1. [Unsatisfactory results of upstream therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for the prevention of recurrent atrial fibrillation].
Disertori M; Zeni P; Quintarelli S; Bonmassari R
G Ital Cardiol (Rome); 2010 Nov; 11(11):829-34. PubMed ID: 21348320
[TBL] [Abstract][Full Text] [Related]
2. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.
Savelieva I; Kakouros N; Kourliouros A; Camm AJ
Europace; 2011 Mar; 13(3):308-28. PubMed ID: 21345926
[TBL] [Abstract][Full Text] [Related]
3. [Upstream therapy of atrial fibrillation in patients with heart failure].
Alboni P; Gianfranchi L; Pacchioni F
G Ital Cardiol (Rome); 2009 Sep; 10(9):566-71. PubMed ID: 19891248
[TBL] [Abstract][Full Text] [Related]
4. Focus on renin-angiotensin system modulation and atrial fibrillation control after GISSI AF results.
Durin O; Pedrinazzi C; Inama G
J Cardiovasc Med (Hagerstown); 2010 Dec; 11(12):912-8. PubMed ID: 20729747
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
Disertori M; Latini R; Maggioni AP; Delise P; Di Pasquale G; Franzosi MG; Staszewsky L; Tognoni G;
J Cardiovasc Med (Hagerstown); 2006 Jan; 7(1):29-38. PubMed ID: 16645357
[TBL] [Abstract][Full Text] [Related]
6. Reviewing the future of renin-angiotensin system blockade: the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation.
Ducharme A; Schiffrin EL
Can J Cardiol; 2010 Dec; 26 Suppl E():21E-23E. PubMed ID: 21620287
[TBL] [Abstract][Full Text] [Related]
7. Therapy with renin-angiotensin system blockers after pulmonary vein isolation in patients with atrial fibrillation: who is a responder?
Berkowitsch A; Neumann T; Kuniss M; Janin S; Wojcik M; Zaltsberg S; Mitrovic V; Pitschner HF
Pacing Clin Electrophysiol; 2010 Sep; 33(9):1101-11. PubMed ID: 20487340
[TBL] [Abstract][Full Text] [Related]
8. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.
Lévy S
Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):220-5. PubMed ID: 16568131
[TBL] [Abstract][Full Text] [Related]
9. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
Zhang Y; Zhang P; Mu Y; Gao M; Wang JR; Wang Y; Su LQ; Hou YL
Clin Pharmacol Ther; 2010 Oct; 88(4):521-31. PubMed ID: 20811347
[TBL] [Abstract][Full Text] [Related]
10. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
Richter B; Derntl M; Marx M; Lercher P; Gössinger HD
Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
[TBL] [Abstract][Full Text] [Related]
11. Inefficiency of renin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart.
Fazio G; Pizzuto C; Sutera L; Guttilla D; Di Gesaro G; Cascio C; Novo G; Assennato P; Novo S
Minerva Cardioangiol; 2007 Jun; 55(3):311-5. PubMed ID: 17534249
[TBL] [Abstract][Full Text] [Related]
12. [Non-antiarrhythmic drug therapy for the prevention of atrial fibrillation?].
Fauchier L; Zannad N; Clementy N; Pierre B; Cosnay P; Babuty D
Ann Cardiol Angeiol (Paris); 2010 Dec; 59 Suppl 1():S28-32. PubMed ID: 21211623
[TBL] [Abstract][Full Text] [Related]
13. Impact of angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers on long-term outcome of catheter ablation for atrial fibrillation.
Tayebjee MH; Creta A; Moder S; Hunter RJ; Earley MJ; Dhinoja MB; Schilling RJ
Europace; 2010 Nov; 12(11):1537-42. PubMed ID: 20682557
[TBL] [Abstract][Full Text] [Related]
14. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
Makkar KM; Sanoski CA; Spinler SA
Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
[TBL] [Abstract][Full Text] [Related]
15. Renin-angiotensin system inhibitors for prevention of recurrent atrial fibrillation: a meta-analysis.
Li TJ; Zang WD; Chen YL; Geng N; Ma SM; Li XD
Int J Clin Pract; 2013 Jun; 67(6):536-43. PubMed ID: 23557493
[TBL] [Abstract][Full Text] [Related]
16. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation.
Al Chekakie MO; Akar JG; Wang F; Al Muradi H; Wu J; Santucci P; Varma N; Wilber DJ
J Cardiovasc Electrophysiol; 2007 Sep; 18(9):942-6. PubMed ID: 17593228
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation.
Anand K; Mooss AN; Hee TT; Mohiuddin SM
Am Heart J; 2006 Aug; 152(2):217-22. PubMed ID: 16875900
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis.
Huang G; Xu JB; Liu JX; He Y; Nie XL; Li Q; Hu YM; Zhao SQ; Wang M; Zhang WY; Liu XR; Wu T; Arkin A; Zhang TJ
Eur J Clin Invest; 2011 Jul; 41(7):719-33. PubMed ID: 21250983
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the renin-angiotensin system for prevention of atrial fibrillation.
Zografos T; Katritsis DG
Pacing Clin Electrophysiol; 2010 Oct; 33(10):1270-85. PubMed ID: 20636314
[TBL] [Abstract][Full Text] [Related]
20. Upstream therapy of atrial fibrillation.
Smit MD; Van Gelder IC
Expert Rev Cardiovasc Ther; 2009 Jul; 7(7):763-78. PubMed ID: 19589113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
